OS Therapies Inc. Files DEFA14A for Annual Meeting

Ticker: OSTX · Form: DEFA14A · Filed: Oct 17, 2025 · CIK: 1795091

Os Therapies Inc DEFA14A Filing Summary
FieldDetail
CompanyOs Therapies Inc (OSTX)
Form TypeDEFA14A
Filed DateOct 17, 2025
Risk Levellow
Pages4
Reading Time4 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, governance, annual-meeting

TL;DR

OS Therapies Inc. filed its proxy statement (DEFA14A) detailing exec pay and board elections for shareholders.

AI Summary

OS Therapies Inc. filed a DEFA14A on October 17, 2025, related to its annual meeting. The filing details executive compensation, board nominations, and other corporate governance matters for the fiscal year ending December 31, 2024. Key proposals include the election of directors and the ratification of PricewaterhouseCoopers LLP as its independent registered public accounting firm.

Why It Matters

This filing provides shareholders with crucial information regarding the company's governance, executive pay, and voting matters, allowing them to make informed decisions at the upcoming annual meeting.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement and does not contain new material financial information or significant strategic changes.

Key Numbers

  • 001-42195 — SEC File Number (Identifies the company's filing history with the SEC)
  • 82-5118368 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

  • OS Therapies Inc. (company) — Filer of the DEFA14A
  • 20251017 (date) — Filing date of the DEFA14A
  • PricewaterhouseCoopers LLP (company) — Proposed independent registered public accounting firm
  • Delaware (jurisdiction) — State of incorporation
  • 1231 (date) — Fiscal year end

FAQ

What is the primary purpose of the DEFA14A filing by OS Therapies Inc.?

The primary purpose is to provide shareholders with information regarding the company's annual meeting, including details on executive compensation, board nominations, and voting matters.

When was the DEFA14A filed by OS Therapies Inc.?

The DEFA14A filing was made on October 17, 2025.

Who is proposed to be ratified as OS Therapies Inc.'s independent registered public accounting firm?

PricewaterhouseCoopers LLP is proposed to be ratified as the independent registered public accounting firm.

What is the fiscal year end for OS Therapies Inc. as indicated in the filing?

The fiscal year end for OS Therapies Inc. is December 31.

What is the principal executive office address for OS Therapies Inc.?

The principal executive office address is 115 Pullman Crossing Road, Suite 103, Grasonville, Maryland 21638.

Filing Stats: 1,078 words · 4 min read · ~4 pages · Grade level 10.6 · Accepted 2025-10-17 17:08:54

Key Financial Figures

  • $0.001 — ch Registered Common Stock, par value $0.001 per share OSTX NYSE American Indi

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On October 17, 2025, OS Therapies Incorporated (the "Company") posted an investor presentation to its website at ir.ostherapies.com. The information on the Company's website is not incorporated by reference into this Current Report on Form 8-K. The Company expects to use the investor presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others. A copy of this investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 is being furnished pursuant to Item 7.01 of Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as may be expressly set forth by specific reference in such a filing.

01. Other Events

Item 8.01. Other Events. Annual Meeting Adjournment On October 14, 2025 at 10:00 a.m., Eastern time, the Company convened its 2025 annual meeting of stockholders (the "Annual Meeting") virtually. The proposals submitted to the Company's stockholders for approval at the Annual Meeting are described in the definitive proxy the Auditor Ratification Proposal (each as defined in the Proxy Statement) received the requisite votes for approval. However, the Company adjourned the Annual Meeting in order to allow additional time to solicit proxies. The adjourned Annual Meeting will reconvene at 10:00 a.m., Eastern time, on October 21, 2025. The reconvened Annual Meeting will still be held in a virtual meeting format accessible at https://meeting.vstocktransfer.com/OSTHERAPIESOCT25 . The close of business on August 20, 2025 will continue to be the record date for the determination of stockholders of the Company entitled to vote at the reconvened Annual Meeting. Stockholders may vote at the reconvened Annual Meeting or by submitting a proxy for the reconvened Annual Meeting. Stockholders of the Company who have previously submitted their proxy or otherwise voted and who do not want to change their vote do not need to take any action. During the period of the adjournment, the Company will continue to solicit votes from its stockholders with respect to the proposals for the Annual Meeting. 1 The Company encourages all stockholders of record as of the close of business on August 20, 2025, who have not yet voted, to do so by October 20, 2025 at 11:59 p.m., Eastern time. Notwithstanding the foregoing, any votes properly received before the close of the reconvened Annual Meeting on October 21, 2025 will be accepted. Proxies previously submitted in resp

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Investor Presentation – OS Therapies Incorporated. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OS THERAPIES INCORPORATED Dated: October 17, 2025 By: /s/ Paul A. Romness, MPH Name: Paul A. Romness, MPH Title: President and Chief Executive Officer 3

View Full Filing

View this DEFA14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.